Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | VNN1 | O95497 | 2/20 | 0.43 |
| ▸ | P4HB | P07237 | 2/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.39 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30807353 | 0.84 | GSK3B (0.51) | GSK3BGRM5VNN1P4HBPDK1 | |
| SCHEMBL4444228 | 0.84 | GSK3B (0.51) | GSK3BGRM5VNN1P4HBPDK1 | |
| SCHEMBL6491742 | 0.83 | GSK3B (0.53) | GSK3BGRM5VNN1P4HBCES2 | |
| SCHEMBL3214756 | 0.79 | PDCD1 (0.58) | GSK3BGRM5PDCD1CD274GAA | |
| SCHEMBL5869222 | 0.78 | GSK3B (0.56) | GSK3BGRM5VNN1PDK1PDK2 | |
| SCHEMBL30973065 | 0.78 | PARP1 (0.50) | CES2CES1 | |
| SCHEMBL7354619 | 0.77 | GSK3B (0.44) | GSK3BGRM5VNN1P4HBPDK1 | |
| SCHEMBL7818216 | 0.77 | GSK3B (0.44) | GSK3BGRM5VNN1P4HBPDK1 | |
| SCHEMBL8245175 | 0.76 | GSK3B (0.56) | GSK3BGRM5VNN1P4HBPDK1 | |
| SCHEMBL8489202 | 0.75 | GSK3B (0.52) | GSK3BGRM5VNN1P4HBPDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190300-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2011-08-04 | — | — | US | disclosed |
| EP-2164326-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | Euro-Celtique, S.A. (LU) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008150447-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190300-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | CACNA1E, CACNA1B, CACNA1S | GSK3B 2037/4885GRM5 701/4885VNN1 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.